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Abstract
Human Immunodeficiency Virus-1 (HIV-1)-associated neurocognitive disorders (HAND) occur, in part, due to the
inflammatory response to viral proteins, such as the HIV-1 transactivator of transcription (Tat), in the central nervous
system (CNS). Given the need for novel adjunctive therapies for HAND, we hypothesized that ibudilast would inhibit Tat-
induced excess production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNFa) in microglial cells.
Ibudilast is a non-selective cyclic AMP phosphodiesterase inhibitor that has recently shown promise as a treatment for
neuropathic pain via its ability to attenuate glial cell activation. Accordingly, here we demonstrate that pre-treatment of
both human and mouse microglial cells with increasing doses of ibudilast inhibited Tat-induced synthesis of TNFa by
microglial cells in a manner dependent on serine/threonine protein phosphatase activity. Ibudilast had no effect on Tat-
induced p38 MAP kinase activation, and blockade of adenosine A2A receptor activation did not reverse ibudilast’s inhibition
of Tat-induced TNFa production. Interestingly, ibudilast reduced Tat-mediated transcription of TNFa, via modulation of
nuclear factor-kappa B (NF-kB) signaling, as shown by transcriptional activity of NF-kB and analysis of inhibitor of kappa B
alpha (IkBa) stability. Together, our findings shed light on the mechanism of ibudilast’s inhibition of Tat-induced TNFa
production in microglial cells and may implicate ibudilast as a potential novel adjunctive therapy for the management of
HAND.
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Introduction
Human Immunodeficiency Virus-1 (HIV-1) enters the central
nervous system (CNS) early after infection, and in many cases may
result in a variety of neurological defects collectively termed HIV-1
associated neurocognitive disorders (HAND) [1]. HAND can
include neurocognitive impairments, motor deficits, or dementias
[2], and continues to significantly impair quality of life despite
efficacious reduction of viral load by highly active anti-retroviral
therapy (HAART) [3,4,5]. Traditionally, the onset of HAND
correlated with CNS viral load, and the neuropathological features
included multinucleated giant cells, reactive astrocytosis, myelin
pallor, and neuronal loss [6,7,8,9]. Recent neuropathologic reports
of severe white matter damage (i.e. leukoencephalopathy) in
patients with HIV-1 infection and on HAART with very low viral
load [10,11,12,13], suggest that additional patterns of primary
brain disease are emerging, possibly due to as yet unexplained
interactions between the virus, vulnerable populations of neural
cells, and HAART [14,15].
The pathogenesis of HAND likely involves a toxic combination
of secreted factors released from HIV-1 infected, brain-resident
macrophage and glia, and oxidative stress, which together impair
neuronal function. HIV-1 productively infects microglia and
perivascular macrophage, the resident phagocytes of the CNS, but
does not infect neurons. This suggests that HIV-1 indirectly
contributes to the neuropathology seen in HAND patients.
Accordingly, neurologic deficits in HAND are more closely
correlated with the presence of activated macrophage and
microglia than with the amount of neuronal apoptosis or viral
RNA [16,17,18]. Soluble viral proteins such as Tat and the
glycoprotein gp120 can be released from infected microglia and
macrophage [19]. Circulating Tat levels have been measured in
patient sera from HIV-1 positive individuals, at levels ranging
from 1–40 ng/mL [20,21], however, local extracellular concen-
trations in the CNS may be much higher, particularly in close
proximity to HIV-1 positive perivascular cells [22]. Tat can also
interact with and activate neighboring, uninfected cells including
microglia, astrocytes, and neurons. Both infected and activated
microglia and astrocytes produce pro-inflammatory cytokines
including tumor necrosis factor-alpha (TNFa) and interleukin-1
beta (IL-1b), which further activate neighboring cells. Infected and
activated cells also produce chemokines such as monocyte
chemotactic protein-1 (MCP-1), thereby attracting more inflam-
matory monocytes and macrophage [23,24]. Thus, circulating Tat
is very likely involved in triggering this vicious inflammatory cycle,
eventually leading to neuron damage and cognitive deficits [20].
It is clear that despite effective control of systemic HIV-1 levels
with HAART, cognitive impairment still persists with a high
prevalence. Considering the failure of antiretroviral therapies to
prevent or reverse cognitive decline mediated by HIV-1, recent
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specifically target neurocognitive impairment. General classes of
drugs being explored in clinical trials include anti-inflammatory
agents such as minocycline (NCT00361257 - http://www.
clinicaltrials.gov identifier), antioxidants such as selegiline
[25,26], and anti-excitotoxic drugs such as memantine [27]. Only
memantine, which is an N-methyl-D-aspartic acid receptor
(NMDAR) blocker, has shown potential neuroprotective proper-
ties as determined by magnetic resonance spectroscopy [27].
Given the need for novel adjunctive therapies for HAND, we
hypothesized that the phosphodiesterase inhibitor, ibudilast, would
inhibit Tat-induced, excess production of pro-inflammatory
cytokines, such as TNFa, in microglial cells.
Ibudilast is a relatively non-selective cyclic AMP phosphodies-
terase (PDE) inhibitor that has been used for decades in Japan to
treat bronchial asthma and post-stroke dizziness [28,29]. Ibudilast
has also recently shown promise as a treatment for neuropathic
pain, in multiple rat models, via its ability to attenuate glial cell
activation [30]. Interestingly, in vitro experiments have shown that
ibudilast has potential as an anti-inflammatory agent, as it can
inhibit lipopolysaccharide (LPS)-induced cytokine production in
microglial cells [31,32]. Ibudilast is also currently being tested in
clinical trials as a treatment for multiple sclerosis (MS), opioid
withdrawal, and neuropathic pain, all of which are conditions
involving aberrant microglial activation and CNS inflammation
[28,33,34]. Other PDE inhibitors, pentoxifylline and rolipram,
have been investigated as anti-inflammatory agents, and have been
shown to inhibit HIV-1 replication [35,36,37]. Because of its
approval for use in humans, as well as its ability to cross the blood
brain barrier and inhibit glial cell activation, ibudilast is an
exciting potential adjunctive therapy for HAND [30]. Here we
investigate the anti-inflammatory properties of ibudilast in the
context of HIV-1-induced neuroinflammation.
Initial experiments in human microglial cells demonstrated that
ibudilast did indeed inhibit Tat-induced pro-inflammatory cyto-
kine production in these cells. Similarly, in BV-2 mouse microglial
cells, ibudilast had an inhibitory effect on Tat-induced TNFa
production. These results are in agreement with previous reports
of ibudilast’s ability to attenuate glial cell activation. Further in vitro
experiments were performed to determine the mechanisms of
ibudilast’s inhibition of TNFa release from microglial cells. These
experiments suggested that ibudilast inhibits Tat-mediated tran-
scription of TNFa via modulation of nuclear factor-kappa B (NF-
kB) signaling. Together, our findings shed light on the mechanism
of ibudilast’s inhibition of Tat-induced TNFa production in
microglial cells and may implicate ibudilast as a potential novel
adjunctive therapy for the management of HAND.
Methods
Reagents
HIV-1 Tat 1–72 was obtained from Philip Ray (University of
Kentucky, Lexington, KY, USA). This recombinant Tat protein
was used at 100 nM (,800 ng/mL) concentration, unless
otherwise noted. Soluble Tat levels in HIV-1 patient sera have
been measured up to 40 ng/mL [20,21]. It has also been shown
that Tat can interact with endogenous glycosaminoglycans and
heparan sulfates, thereby potentially lowering its measurable
concentration in vivo [38]. Therefore, it is likely that Tat
concentrations surrounding HIV-1-infected cells are much higher
[22]. In addition, Tat’s exceedingly strong affinity for other
proteins and glass/plastic, and its temperature susceptibility, make
it impossible to determine exactly what fraction of the Tat
‘‘starting dose’’ actually reaches the experimental specimen, thus
likely leading to an underestimation of Tat functions in vitro [39].
Finally, Tat’s effects in vivo are likely to occur over long-term
chronic exposures. Chronic, low dose in vivo effects of any reagent
are often appropriately modeled in vitro, by proportionately higher
doses of that same reagent, over more acute time frames. For these
reasons, and in order to be consistent with previous experiments
from our laboratories, and others, we use 100 nM Tat for these
experiments, which is at the lower end of the Tat dose range seen
with many comparable studies, and which many studies have
found to be an appropriate Tat dose by which to model Tat’s in
vivo effects in vitro.
Ibudilast was obtained from Santa Cruz Biotechnologies Inc.,
(Santa Cruz, CA, USA). Okadaic acid (Oka) was purchased from
Calbiochem/Millipore (Billerica, MA, USA). SB203580 and 3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). ZM241385
and CGS21680 were purchased from Tocris Bioscience, (Ellisville,
MO, USA). MG-132 was purchased from BioMol International/
Enzo Life Sciences (Plymouth Meeting, PA, USA). DMSO was used
as a vehicle control. Anti-Tat antibody was obtained from the AIDS
Research and Reference Reagent Program (Germantown, MD,
USA) and non-immune control serum (IgG)was obtained from Santa
Cruz Biotechnologies Inc., (Santa Cruz, CA, USA). Both antibodies
were used at a concentration of 8 mg/mL.
Cell Cultures
Human microglial cells that were isolated from fetal human
brain were obtained from Clonexpress (Gaithersburg, MD, USA)
and were maintained in 50:50 DMEM: F-12 supplemented with
5% FBS and 10 ng/mL of M-CSF.
The murine microglial cell-line (BV-2) was obtained from Dr.
R. Donato (University of Perugia, Perugia, Italy). These cells were
maintained in DMEM containing 10% FBS, 2 mM glutamine,
and antibiotics, by standard procedures.
ELISA
TNFa levels were measured in culture supernatants (pre-cleared
by brief centrifugation) by using a mouse TNFa ELISA kit
(eBioscience, San Diego, CA, USA) according to the manufactur-
er’s instructions. This kit has a minimum sensitivity threshold of
8 pg/mL. Briefly, 50 mL of cell culture supernatant was incubated
in a 96-well plate pre-coated with a TNFa-specific monoclonal
antibody for 1.5 h. After extensive washing, binding of TNFa was
detected by incubation with biotinylated antibodies, followed by
streptavidin-peroxidase; colorimetric enzyme assays were per-
formed to detect bound TNFa.
Other cytokine levels were measured using Bio-Plex Multi-Plex
analysis for detecting a panel of multiple cytokines from a single
sample (Bio-Rad, Hercules, CA, USA). Briefly, this technology
uses multiple spectrally identifiable polystyrene beads, each coated
with a different anti-cytokine antibody, followed by target, then
secondary antibody binding, to detect multiple cytokines from a
single sample in typical sandwich-assay fashion. This assay was
utilized to measure levels of TNFa, IL-1b, IL-6, and MCP-1 in
Tat-treated, primary human microglia supernatant samples, as
previously described [40,41].
MTT Assay
BV-2 cells (1.2610
5) were plated in a 24-well plate and were
treated with increasing concentrations of ibudilast or DMSO
control for 7 h. 106 MTT was added to the wells and the cells
were incubated for an additional 1 h at 37uC. After removal of the
media, MTT solvent (4 mM HCl, 0.1% NP40, in isopropanol)
was added to dissolve the formazan dye. The optical density was
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compared to the untreated (NT) sample.
p38 MAP Kinase Activity Assay
p38 MAP kinase activity levels were measured in BV-2 cell
lysates using a p38 kinase activity kit (Cell Signaling Technology,
Danvers, MA, USA) according to the manufacturer’s instructions.
Briefly, phosphorylated p38 was immunoprecipitated from 200 mL
of whole cell lysate using a phospho-p38 MAP kinase monoclonal
antibody crosslinked to agarose hydrazide beads. The antibody-
bead pellet was then incubated with an Activating Transcription
Factor-2 (ATF-2) fusion protein as the substrate. ATF-2
phosphorylation was detected by immunoblot analysis using a
phospho-ATF-2 (Thr71) antibody. Equal protein content among
the samples was verified using immunoblot analysis for total p38
and a-Tubulin levels in the cell lysate supernatant that was
collected after the immunoprecipitation.
Plasmids
The luciferase reporter construct driven by NF-kB and the
RelA expression plasmid were obtained from Dr. S. C. Sun (MD
Anderson Cancer Center, University of Texas, Houston, TX,
USA). The luciferase reporter construct driven by the mouse
TNFa (mTNFa) promoter was obtained from Dr. Dmitry
Kuprash (Engelhardt Institute of Molecular Biology, Moscow,
Russia).
Transient Transfections
BV-2 cells were transfected with plasmid DNA using
Nucleofector (Amaxa/Lonza, Basel, Switzerland; Walkersville,
MD, USA). For nucleofection, 10610
6 cells were transfected
with 10 mg total plasmid DNA. Transfected cells were plated at
3.5610
5 cells/well in a 24-well plate and incubated for 24 h
prior to treatment. Media was changed 4 h after transfection
and again prior to treatment to reduce cell toxicity. In order to
determine transfection efficiency, a separate aliquot of BV-2
cells was transfected with a p-Max-GFP expressing vector
( A m a x a / L o n z a ,B a s e l ,S w i t z e r l a n d ;W a l k e r s v i l l e ,M D ,U S A ) ,
and 24 h post-transfection, greater than 90% of BV-2 cells were
GFP-positive.
Luciferase Assays
Luciferase reporter plasmids containing either NF-kB respon-
sive elements upstream of a firefly luciferase gene or the mouse
TNFa promoter region upstream of a firefly luciferase gene were
transfected into BV-2 cells using Nucleofector (Amaxa/Lonza,
Basel, Switzerland; Walkersville, MD, USA). 24 h post-transfec-
tion, cells were either left untreated or were incubated for 8 h with
100 nM Tat. Cell lysates were prepared using 16 reporter lysis
buffer (Promega Life Sciences, Madison, WI, USA), and luciferase
activity was measured with a SpectraMax M3 Plate Reader
(Molecular Devices, Sunnyvale, CA). In these assays, total protein
amount as determined by Bradford assay (Bio-Rad, Hercules, CA,
USA), was used to normalize the samples. In the case of luciferase
assays without Tat treatment, co-transfection with a Renilla
luciferase reporter driven by the constitutively active herpes
simplex virus type 1 thymidine kinase (HSV-1 TK) promoter was
used as an internal control for transfection efficiency. In the case of
luciferase assays with Tat treatment, parallel transfection with a
luciferase reporter plasmid containing responsive elements of the
OCT-1 transcription factor upstream of a firefly luciferase gene
was used as a control for the specificity of Tat’s effect on
transcription.
Protein Phosphatase Activity Assay
BV-2 cells (4.6610
5) were plated in 6-well plates and were
treated with 50 mM ibudilast for the indicated periods of time.
Cells were washed in phosphate buffered saline (PBS) and whole
cell lysates were collected in ELB buffer (50 mM HEPES (pH 7),
250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 10 mM NaF,
0.1 mM Na3VO4,5 0 mM ZnCl2, supplemented with 0.1 mM
PMSF, 1 mM DTT, and a mixture of protease inhibitors,
phosphatase inhibitors were not added). PP2A activity was
measured with a Ser/Thr phosphatase assay kit (Promega Life
Sciences, Madison, WI, USA) according to the manufacturer’s
protocol. Briefly, samples containing 5 mg of cell protein were
added to a solution containing the peptide substrate (100 mM) in a
96-well plate and incubated for 10 min. Then a Malachite Green
solution was added (50 mL) and absorbance (560 nm) was
measured on a DTX 880 Microplate Reader (Beckman Coulter,
Brea, CA). Phosphate release was determined by comparing
absorbance with a standard curve.
Immunoblotting Assays
Following the indicated treatments, whole cell lysates were
prepared in ELB buffer (50 mM HEPES (pH 7), 250 mM NaCl,
0.1% Nonidet P-40, 5 mM EDTA, 10 mM NaF, 0.1 mM
Na3VO4,5 0 mM ZnCl2, supplemented with 0.1 mM PMSF,
1 mM DTT, and a mixture of protease and phosphatase
inhibitors). Cellular debris was removed by high-speed centrifu-
gation. Lysates were fractionated on 7.5% SDS-PAGE gels and
protein was electrophoretically transferred to Hybond ECL
nitrocellulose membrane (GE Healthcare Bio-Sciences Corpora-
tion, Piscataway, NJ, USA). The membranes were analyzed for
immunoreactivity with primary antibodies raised against IkBa
(1:1000), RelA (1:1000), or a-Tubulin (1:1000; all from Santa Cruz
Biotechnologies Inc., Santa Cruz, CA, USA), p38 MAP kinase
(1:1000), Phospho-p38 MAPK (1:1000), RelA P-S276 (1:1000),
RelA P-S536 (1:1000), or PP2Ac (1:1000; all from Cell Signaling
Technology, Danvers, MA, USA). Bound antibodies were
detected by species-specific, horseradish peroxidase (HRP)-conju-
gated secondary antibodies (1:3000, GE Healthcare Bio-Sciences
Corporation, Piscataway, NJ, USA), followed by addition of ECL
reagent (Pierce Biotechnology/Thermo Fisher Scientific, Rock-
ford, IL, USA) and subsequent exposure to x-ray film. Equal
loading and uniformity of protein transfer to the nitrocellulose
membrane were verified by stripping and reprobing the
membranes with primary antibodies specific to a-Tubulin.
Real-Time RT-PCR Analyses
Total RNA was isolated from treated BV-2 cells (2.5610
5) using
the Roche High Pure RNA Isolation kit (Roche Applied Science,
Indianapolis, IN, USA) according to the manufacturer’s protocol.
Complementary DNA (cDNA) synthesis was performed using 2 mg
total RNA, oligo-dT primers, and the Superscript III first-strand
synthesis system (Invitrogen, Carlsbad, CA, USA). Gene-specific
primer sequences were as follows: 1) TNFa primers: forward 59-
ACTCCAGAACATCTTGGAAATAGC-39, reverse 59-GCGG-
ATCATGCTTTCTGTGC-39; 2) GAPDH primers: forward 59-
TGATGACATCAAGAAGGTGGTGAA-39, reverse 59-TCCT-
TGGAGGCCATGTAGGCCAT-39. Real-time RT-RCR was
performed using iQ
TM SYBRH Green PCR Supermix (Bio-Rad,
Hercules, CA, USA) and 100 nM gene-specific forward and
reverse primers in 20 mL total volume. After denaturation for
3 min. at 95uC, the PCR was run for 40 cycles of 95uC for 30 sec.,
primer-specific melting (Tm uC) for 1 min., and 72uC for 30 sec.
using an iCycler instrument (Bio-Rad, Hercules, CA, USA).
GAPDH served as an internal control in these experiments.
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Mean data values and the standard error of the mean (SEM)
were calculated for each variable. One-way ANOVA followed by
Bonferroni’s test for multiple comparisons was used to analyze
data involving the analysis of multiple sample groups. A value of
p,0.05 was designated as statistically significant.
Results
Ibudilast inhibits Tat-induced pro-inflammatory cytokine
production in microglial cells
Multiple reports have shown that ibudilast can inhibit both LPS
and interferon-gamma (IFN-c)-induced production of pro-inflam-
matory molecules in microglial cells, thus highlighting the anti-
inflammatory activities of this drug [32,42]. This led us to
hypothesize that ibudilast may inhibit Tat’s effects on microglial
cells. Although exposure of microglial cells to LPS, IFN-c, and Tat
can all similarly result in cytokine synthesis and NF-kB activation,
the upstream signaling events leading to this cytokine production
are vastly different among these varying stimuli. For example, LPS
is recognized by Toll-like receptor 4 (TLR4), leading to NF-kB
activation, whereas IFN-c activates the IFN-c receptor (IFN-cR),
leading to activation of the Janus kinase (JAK)/signal transducers
and activators of transcription (STAT) pathway. Alternatively,
exposure of microglial cells to Tat does not result in TLR or IFN-
cR activation. Extracellular Tat can enter cells in an active form
[38,43], leading to the activation of multiple signaling pathways
including NF-kB and MAP kinase cascades. Activated microglia
are believed to be centrally involved in HAND-associated
neuropathology as pro-inflammatory factors, such as TNFa,
released from infected and activated macrophage and glial cells
play a central role in the inflammatory cycle that eventually leads
to neuron damage and cognitive deficits [44,45]. We first used a
multi-plex cytokine array assay to determine whether ibudilast
altered Tat-induced pro-inflammatory cytokine and chemokine
production in human microglial cells. These results (Figure 1A)
indicated a profound reduction in Tat-induced production of
TNFa and IL-1b by ibudliast. Although not significant, there was
also a trend toward dose-dependent inhibition of Tat-mediated IL-
6 and MCP-1 production by ibudilast. Our results for MCP-1 are
in agreement with previous reports that human monocytes and
monocyte-derived macrophage have high basal levels of MCP-1
production in the absence of pro-inflammatory stimuli [46,47].
Based on previously published results, MCP-1 production is
induced after 12–24 h incubation with Tat [48,49]. Therefore, it is
likely that with a longer treatment time with Tat, we would have
seen a more robust increase in MCP-1 production. In addition,
little is known about the temporal relationship between TNFa, IL-
1b, IL-6, and MCP-1 production caused by Tat in microglial cells
in vivo. These results in human microglial cells strongly support an
anti-inflammatory role of ibudilast.
We next focused on ibudilast’s ability to inhibit Tat-induced
TNFa synthesis in the mouse microglial BV-2 cell line, which is
genetically manipulatable. These cells are also widely used for
studies related to inflammation induced by generic inflammatory
mediators [50,51,52], and those encoded by HIV-1 [53,54].
Following an 8 h 100 nM Tat treatment of these cells, we
collected culture supernatants and measured TNFa levels by
ELISA. The results shown in Figure 1B reveal the ability of
ibudilast to inhibit Tat-mediated TNFa production in mouse
microglial BV-2 cells, further supporting an anti-inflammatory role
for ibudilast in the context of HIV-1. As shown in Figure 1, there is
slightly less inhibition of TNFa by ibudilast in BV-2 cells than in
human microglial cells. This could be due to the fact that BV-2
cells are rapidly dividing, whereas the human microglial cells are
non-dividing. We also confirmed that ibudilast’s inhibition of
TNFa production was not due to cellular toxicity. The MTT assay
was used as a measure of cell viability. As shown in Figure 1C,
treatment of BV-2 cells with increasing concentrations of ibudilast
did not result in significant cell death.
Blockade of adenosine A2A receptor does not reverse
ibudilast’s inhibition of Tat-mediated TNFa production
Next we examined the mechanisms by which ibudilast inhibits
Tat-induced TNFa production. PDE inhibition is known to affect
adenosine receptor activation [55,56,57], and adenosine is an
important director of inflammatory responses [58,59,60]. Aden-
osine receptor activation can inhibit the production of TNFa, and
in the context of HIV-1, it has been shown that adenosine A2A
receptor activation inhibits Tat-induced TNFa production in
human monocytes [61]. Therefore, we speculated that ibudilast’s
inhibition of Tat-induced TNFa production might involve
modulation of adenosine A2A receptor activation. As shown in
Figure 2A, we confirmed that activation of the A2A receptor with
the agonist CGS21680 (1 mM) inhibited Tat-induced TNFa
production in mouse microglial cells as measured by TNFa
ELISA. This inhibition was reversed with the A2A receptor
antagonist ZM241385 (100 nM). Pre-treatment with an anti-Tat
antibody also blocked Tat-induced TNFa production, whereas a
control non-immune IgG had no effect on Tat-induced TNFa.
This indicated that the TNFa production was Tat-specific
(Figure 2A). However, blockade of A2A receptor activation with
increasing concentrations of ZM241385 did not reverse the
inhibition of Tat-induced TNFa release by ibudilast in mouse
microglial cells (Figure 2B), suggesting that ibudilast’s inhibition of
TNFa does not involve adenosine A2A receptor activation.
Tat-induced activation of p38 MAP kinase is not affected
by ibudilast
To further examine the mechanisms of ibudilast’s inhibition of
Tat-mediated TNFa production, we looked at the activation of
p38 MAP kinase, which is known to play an important role in the
production of pro-inflammatory cytokines [62]. p38 MAP kinase is
also a known target for other PDE inhibitors such as pentoxifylline
[63]. Using an antibody that recognizes phosphorylated p38, we
did see an increase in the phosphorylation of p38 induced by
15 min. 100 nM Tat treatment (Figure 3A). Pre-treatment with
increasing concentrations of ibudilast did not affect Tat-induced
p38 phosphorylation. Under these conditions total p38 levels
(protein loading control) were not altered. In addition, there was
an approximately 15-fold increase in p38 MAP kinase activity
induced by 20 min. 100 nM Tat treatment, as measured by an in
vitro kinase assay (Figure 3B). Pre-treatment with ibudilast did not
inhibit this Tat-induced increase in p38 activity. As a positive
control, the p38 inhibitor, SB203580, did reduce Tat-mediated
p38 kinase activity. Densitometric analysis of the phospho-ATF-2
bands versus the total p38 bands is shown in Figure 3B.
Ibudilast inhibits Tat-induced TNFa production through
serine/threonine protein phosphatase activity
PDE inhibitors have been shown to modulate protein
phosphatase activity [64,65], and the involvement of protein
phosphatases in the inhibition of Tat-induced TNFa production
has been well characterized [61]. Thus, we predicted that the
inhibitory actions of ibudilast on TNFa production could be
regulated by protein phosphatase activation. As expected,
ibudilast’s inhibition of Tat-induced TNFa production was
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microglial cells (1610
5) were left untreated (NT) or were treated with Tat (100 nM) for 8 h with or without pre-treatment for 30 min. with increasing
concentrations of ibudilast or vehicle (Veh), as indicated. TNFa, IL-1b, IL-6, and MCP-1 levels in culture supernatants were analyzed by Multi-Plex
cytokine array, as described in Methods. The Tat+Veh-treated samples were set to 100% and all other samples were compared to this value. Results
are shown as mean 6 SD of values derived from two replicates from a single representative experiment. Statistical significance (***, p,0.001; *,
p,0.05) is indicated, as compared to Tat+Veh-treated cells. The average cytokine/chemokine concentration of the Tat+Veh-treated sample was as
follows; TNFa: 8166 pg/mL, IL-1b: 3.3 pg/mL, IL-6: 6027 pg/mL, and MCP-1: 1480 pg/mL. B, Similarly, murine microglial cells (BV-2; 1.2610
5) were left
untreated (NT) or were treated with Tat (100 nM) for 8 h with or without pre-treatment for 30 min. with increasing concentrations of ibudilast or
vehicle (Veh), as indicated. TNFa release was measured by ELISA. Results are shown as mean 6 SEM of values derived from three replicates from a
single representative experiment; three total experiments were performed. Statistical significance (p,0.001) is indicated, as compared to Tat+Veh-
treated cells (***). The TNFa concentration of the Tat+Veh-treated sample was 1861 pg/mL. C, BV-2 cells (1.2610
5) were left untreated (NT) or were
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threonine protein phosphatase inhibitor (Figure 4A). This
indicated that the anti-TNFa effects of ibudilast were protein
phosphatase dependent. Additionally, we measured phosphatase
activity in whole cell extracts from ibudilast-treated BV-2 cells.
Ibudilast significantly increased serine/threonine phosphatase
activity after 60 min. (Figure 4B). Besides increasing phosphatase
activity, ibudilast treatment also increased levels of the catalytically
active PP2Ac subunit as detected by immunoblot analysis
(Figure 4C). Together these results indicate that ibudilast
treatment leads to higher PP2A activity.
Ibudilast’s reduction of Tat-mediated TNFa is at the
transcriptional level
Considering that protein phosphatase activation can affect
multiple signaling pathways [66,67,68], we predicted that ibudilast
Figure 2. Inhibition of Tat-induced TNFa production by ibudilast is not reversed by blockade of adenosine A2A receptor. A, BV-2 cells
(1.5610
5) were left untreated (NT) or were treated with Tat (100 nM) for 8 h with or without pre-treatment for 30 min. with either anti-Tat or control
IgG antibodies (8 mg/mL) or adenosine A2A receptor agonist, CGS21680 (CGS, 1 mM) or antagonist, ZM241385 (ZM, 100 nM), as indicated. TNFa
release was measured by ELISA. The Tat-treated samples were set to 100% and all other samples were compared to this value (the TNFa
concentration for this sample was 3475 pg/mg total protein content). Results are shown as mean 6 SEM of values derived from four replicates from a
single representative experiment; two total experiments were performed. Statistical significance (p,0.001) is indicated, as compared to Tat-treated
cells (***) or as compared to Tat+CGS-treated cells (###). B, BV-2 cells (1.2610
5) were left untreated (NT) or were treated with Tat (100 nM) for 8 h
with or without pre-treatment for 30 min. with ibudilast (Ib, 50 mM) or vehicle (Veh) alone or together with increasing concentrations of the
adenosine A2A receptor antagonist, ZM241385, as indicated. TNFa release was measured by ELISA. The Tat+Veh-treated samples were set to 100%
and all other samples were compared to this value (the TNFa concentration for this sample was 696.2 pg/mL). Results are shown as mean 6 SEM of
values derived from three replicates from a single representative experiment; two total experiments were performed. Statistical significance is
indicated, as compared to Tat+Veh-treated cells (p,0.05, *) or as compared to Tat+ZM241385-treated cells (p,0.001, ###).
doi:10.1371/journal.pone.0018633.g002
treated with increasing concentrations of ibudilast or vehicle (Veh), as indicated, for 8 h. The MTT assay was used as a measure of cell viability. Percent
survival was calculated as compared to the untreated sample. Results are shown as mean 6 SEM of values derived from four replicates from a single
representative experiment; two total experiments were performed.
doi:10.1371/journal.pone.0018633.g001
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We used quantitative real-time PCR (qRT-PCR) to determine
whether ibudilast altered Tat-induced TNFa transcript levels in
mouse microglial cells. Total RNA isolated from BV-2 cells treated
with Tat with or without ibudilast pre-treatment was used to
measure the abundance of TNFa transcripts. As compared to non-
treated cells, there was an approximately 12-fold increase in TNFa
mRNA levels in Tat-treated cells. Pre-treatment with vehicle
control did not reduce the Tat-mediated increase in TNFa mRNA
levels, however, pre-treatment with increasing concentrations of
ibudilast dose-dependently inhibited Tat-induced TNFa mRNA
levels (Figure 5).
Inhibition of Tat-mediated TNFa transcription by
ibudilast involves modulation of NF-kB
We, and others, have shown that NF-kB signaling plays an
important role in Tat-induced TNFa production [54,69]. Indeed,
activation of NF-kB is also affected by protein phosphatase activity
[67,70]. To better understand how ibudilast inhibits Tat-induced
TNFa transcription, we used a reporter gene assay. To do this,
BV-2 cells were transiently transfected with a luciferase reporter
plasmid in which the luciferase gene is placed under direct control
of the NF-kB responsive element [71]. These cells were then
treated with Tat either alone or together with vehicle control or
ibudilast. Our results confirmed that pre-treatment with ibudilast
inhibits activation of endogenous NF-kB induced by 8 h 100 nM
Tat treatment (Figure 6A). A parallel transfection with a luciferase
reporter plasmid in which the luciferase gene is downstream of
OCT-1 transcription factor response elements was used as a
control for the specificity of ibudilast’s inhibition of NF-kB. We
performed additional luciferase assays in which BV-2 cells were
transfected with the NF-kB reporter together with either a plasmid
expressing RelA, which is a major component of active NF-kB
dimers, or an empty vector control plasmid. The total amount of
DNA in each transfection was kept constant. Over-expression of
RelA bypasses signaling defects by enriching functionally active
homodimers in the nucleus due to a stoichiometric imbalance
between over-expressed RelA and endogenous inhibitors such as
p100 and inhibitor of kappa B-alpha (IkBa). Interestingly, we did
not see a reduction in luciferase expression induced by over-
expression of RelA with ibudilast treatment (Figure 6B). Co-
transfection with a Renilla luciferase reporter driven by the
constitutively active HSV-1 TK promoter was used as an internal
control for transfection efficiency. Similarly, BV-2 cells were
transfected with the mouse TNFa-promoter luciferase reporter
together with a plasmid expressing RelA. These cells were then
treated with Tat either alone or together with vehicle control or
ibudilast. Our results confirmed that over-expression of RelA was
able to overcome ibudilast’s inhibition of TNFa promoter activity
(Figure 6C). As in Figure 6A, a parallel transfection with an OCT-
1 luciferase reporter confirmed the specificity of ibudilast’s
inhibition of TNFa promoter activation. Together these results
suggest that ibudilast inhibits the NF-kB signaling cascade, since
this inhibition was overcome by RelA over-expression.
Inhibition of NF-kB can take place at multiple steps within the
NF-kB signal transduction pathway. For example, the nuclear
translocation of NF-kB proteins such as RelA could be blocked, or
the transcriptional activity of these proteins in the nucleus could be
inhibited. The IkB molecules interact with NF-kB dimers, leading
to their retention in the cytoplasm in resting cells, as well as
blocking the DNA binding activity of NF-kB [72]. Upon activation
of the NF-kB pathway, IkBa is phosphorylated by the inhibitor of
kappa B kinase (IKK) complex and subsequently targeted for
ubiquitination and proteolytic degradation, thus freeing NF-kB
dimers to move to the nucleus where they can activate
transcription [73]. Indeed, high levels of IkBa were detected in
whole cell lysates from untreated BV-2 cells, and as expected,
incubation of these cells with Tat for 15 min. led to the rapid
degradation of IkBa (Figure 6D). However, we did not see a
reversal of this Tat-induced IkBa degradation by pre-treatment
with increasing concentrations of ibudilast (Figure 6D). Addition-
ally, pre-treatment with a proteasomal inhibitor, MG-132, did
significantly reverse the Tat-induced IkBa degradation, as
expected [74,75]. Under these conditions, no change was observed
in a-Tubulin protein levels (Figure 6D). Likewise, analogous to the
results shown in Figure 6D, using immunofluorescence analysis,
we observed nuclear translocation of RelA in 1 h 100 nM Tat-
Figure 3. Ibudilast does not inhibit Tat-induced activation of
p38 MAP kinase. A, BV-2 cells (1.2610
5) were left untreated (NT) or
were treated with Tat (100 nM) for 15 min. with or without pre-
treatment for 5 min. with increasing concentrations of ibudilast, as
indicated. Whole cell lysates were subjected to immunoblot analysis
using either phospho-p38 MAPK-specific (upper panel) or p38 MAPK-
specific (lower panel) antibodies. The results of a single representative
experiment are shown; three total experiments were performed. B, BV-2
cells (2.4610
5) were left untreated (NT) or were treated with Tat
(100 nM) for 20 min. with or without pre-treatment for 10 min. with
increasing concentrations of ibudilast or the p38 MAP kinase inhibitor,
SB203580, as indicated. Whole cell lysates were subjected to
immunoprecipitation with an immobilized phospho-p38 MAP kinase
antibody. Precipitated p38 was incubated with an ATF-2 fusion protein
substrate. Phosphorylated ATF-2 levels were determined by immuno-
blot analysis with a phospho-ATF-2-specific antibody (top panel). Whole
cell lysate supernatants collected after immunoprecipitation were
subjected to immunoblot analysis using p38-specific (middle panel)o r
a-Tubulin-specific (lower panel) antibodies. Protein levels were quanti-
fied using ImageJ software (bottom graph). Phospho-ATF-2 levels were
normalized to total p38 MAPK levels and fold change compared to NT
was calculated. The results of a single representative experiment are
shown; two total experiments were performed.
doi:10.1371/journal.pone.0018633.g003
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inhibited by pre-treatment with ibudilast (data not shown).
The transcriptional activity of RelA is partially controlled by
post-translational modifications, including phosphorylation [76].
Through the activation of multiple signaling cascades, Tat and
Tat-induced factors such as TNFa, are known to induce the
phosphorylation of RelA at multiple sites [77,78,79]. Using
antibodies that specifically recognize serine 276 and serine 536
phosphorylated RelA, we were able to confirm that RelA is indeed
phosphorylated at both of these sites in Tat-treated BV-2 cells, but
that ibudilast does not affect this Tat-induced phosphorylation of
RelA (Figure 6E). Although the precise mechanism of ibudilast’s
action on NF-kB transcriptional activity remains unknown, we
concluded that ibudilast may block NF-kB activity in a manner
that is independent of nuclear translocation and phosphorylation
of RelA.
Discussion
We, and others, have previously demonstrated that TNFa
produced from HIV-1 infected or activated macrophage and
microglia in the CNS is a major player in HIV-1-induced
neuroinflammation, that eventually leads to neuron damage and
cognitive impairment [54,80,81,82]. Both neuroinflammation and
monocyte/macrophage infiltration into the CNS are critical
factors in the development of HAND, despite effective control of
HIV-1 levels with HAART. Antiretroviral drugs target and
effectively control viral replication, but once proviral DNA has
integrated into the host chromosome, the production of early viral
proteins such as Tat, a known neurotoxin, is not affected by these
antiretrovirals [83]. It is also important to consider the limited
CNS penetration and neurotoxicities of many antiretroviral drugs
themselves [84,85]. For these reasons, mechanisms to inhibit
macrophage and microglial activation and neuroinflammation
deserve further investigation in the pursuit of adjunctive therapies
designed to protect CNS cells from damage caused by HIV-1. A
myriad of possible adjunctive treatment compounds have been
tested in vitro. Compounds targeting cellular signaling pathways
including glycogen synthase kinase-3 beta (GSK3b) and mixed
lineage kinase-3 (MLK3), as well as compounds targeting
pathological outcomes of HIV-1 infection in the CNS including
excitotoxicity, oxidative stress, and inflammation showed initial
promise in vitro, however, only a handful of these treatments have
moved into clinical trials. To date, only memantine, an NMDAR
Figure 4. Ibudilast inhibits Tat-induced TNFa production in a protein phosphatase dependent manner. A, BV-2 cells (1.2610
5) were left
untreated (NT) or were treated with Tat (100 nM) for 8 h with or without pre-treatment for 30 min. with ibudilast (Ib, 50 mM) or vehicle (Veh) alone or
together with the protein phosphatase inhibitor, okadaic acid (Oka, 50 nM). TNFa release was measured by ELISA. The Tat+Veh-treated samples were
set to 100% and all other samples were compared to this value (the TNFa concentration for this sample was 1861 pg/mL). Results are shown as mean
6 SEM of values derived from three replicates from a single representative experiment; two total experiments were performed. Statistical significance
is indicated, as compared to Tat+Veh-treated cells (p,0.001, ***) or as compared to Tat+Ib-treated cells (p,0.01, ##). B, Serine/Threonine
phosphatase activity was measured in whole cell lysates from BV-2 cells (4.6610
5) treated with ibudilast (50 mM) for the indicated periods of time.
Results are shown as mean 6 SEM of values derived from three replicates from a single representative experiment; two total experiments were
performed. Statistical significance (p,0.001) is indicated, ***. C, BV-2 cells (1.2610
5) were left untreated (NT) or were treated with ibudilast (50 mM) for
8 h or 24 h, as indicated. Whole cell lysates were subjected to immunoblot analysis using either PP2Ac-specific (upper panel) or a-Tubulin-specific
(lower panel) antibodies. The results of a single representative experiment are shown; two total experiments were performed.
doi:10.1371/journal.pone.0018633.g004
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from HIV-1-induced neurocognitive damage [27]. The persistence
of HAND despite effective HAART treatment, together with the
lack of effective available adjunctive therapies for HAND,
highlight the need for studies investigating novel adjunctive
therapies.
In addition to ibudilast, other PDE inhibitors have been
considered as anti-inflammatory agents in the context of HIV-1
infection. For example, initial in vitro experiments with pentoxifyl-
line, a non-selective PDE inhibitor, showed that this drug inhibited
microglial cell activation and the production of pro-inflammatory
cytokines [86]. Also, in peripheral blood mononuclear cells
(PBMCs) from HIV-1 positive, pentoxifylline-treated patients,
there was lower LPS-induced TNFa release as compared to cells
from HIV-1 positive, non-treated patients [36]. However, it was
subsequently shown that the maximum tolerated dose of
pentoxifylline in patients did not produce plasma concentrations
high enough to match concentrations necessary to achieve the
anti-inflammatory effects seen in vitro [87]. Additionally rolipram, a
specific inhibitor of PDE 4, has been shown to suppress cytokine
production and to inhibit HIV-1 replication in T-cells [35]. The
low plasma concentrations of pentoxifylline, together with the
gastrointestinal side effects associated with the use of PDE
inhibitors, has limited further investigation of several PDE
inhibitors for use in the context of HIV-1 infection.
NF-kB signaling plays an important role in the production of
TNFa. As such, it has been shown that pentoxifylline inhibits NF-
kB as a mechanism for its inhibition of TNFa [31,88,89,90]. Also,
increased cAMP levels have been shown to inhibit NF-kB
transcriptional activity [91]. Considering this, we chose to
investigate the effect of ibudilast on NF-kB as a potential
mechanism for its inhibition of TNFa. As predicted, we did see
a significant inhibition of Tat-induced NF-kB activation by
ibudilast. Interestingly, we did not see a reversal of Tat-mediated
IkBa degradation with ibudilast pre-treatment. This lack of IkBa
stabilization by ibudilast suggests that the NF-kB inhibition by
ibudilast occurs after RelA nuclear translocation, which is
mediated by IkBa degradation. The transcriptional activity of
RelA is partially controlled by multiple post-translational modifi-
cations, including phosphorylation, ubiquitination, and acetylation
[76]. However, we did not see a reduction in Tat-induced RelA
phosphorylation with ibudilast pre-treatment. Other possibilities
for NF-kB inhibition in the nucleus include additional post-
translational modifications, such as acetylation or ubiquitination,
dimer exchange, or interactions with nuclear proteins such as the
transcriptional coactivator and acetyltransferase, p300. Given the
complexity of the regulation of NF-kB activity, it is not surprising
that ibudilast’s inhibition of NF-kB signaling appears to involve a
post-translational modification of NF-kB, following normal
mobilization of these molecules into the nucleus. Ibudilast could
also potentially be inhibiting the DNA binding activity of NF-kB,
as has been reported with the type 3 PDE inhibitor, cilostazol [52].
The precise mechanism of ibudilast’s action on NF-kB transcrip-
tional activity is currently under investigation in our laboratory.
In addition, there are hundreds of NF-kB inhibitors, all of which
have greatly contributed to NF-kB research, but have limited
clinical applications because of considerable toxicity to healthy
cells, as NF-kB signaling is intricately involved in multiple cellular
processes [92]. Considering the multiple functions of NF-kB
signaling, specifically in the CNS [93], drugs such as ibudilast, with
only partial inhibition of NF-kB in the context of HIV-1 in the
CNS, could be beneficial.
Based on ibudilast’s history of use in patients, this drug deserves
further study as an anti-inflammatory agent in the context of HIV-
1-induced neuroinflammation. Recent studies have shown that
combinations of PDE inhibitors can synergistically suppress TNFa
production by microglia at much lower concentrations than any
single PDE inhibitor alone [32,42]. This could circumvent the
problem of low patient plasma concentrations encountered with
pentoxifylline treatment. It is also important to emphasize the
tolerability of ibudilast in patients, as only mild gastrointestinal
side effects, such as nausea and diarrhea, have been reported
[28,29]. Indeed, ibudilast has been used for decades to treat
bronchial asthma in Japan, and is being tested in clinical trials as a
treatment for MS, opioid withdrawal, and neuropathic pain.
Additionally, ibudilast has been shown to effectively cross the
blood brain barrier and has been measured in rat brain tissue at
concentrations close to plasma levels [30].
Considering ibudilast’s potential ablity to inhibit or resolve CNS
inflammation, there could be additional benefits such as limiting
viral spread by reducing the inflammation-induced influx of
monocytes into the CNS. In addition, TNFa and other related
cytokines have wide-ranging neuromodulatory and even neuro-
protective functions [94]. As such, ibudilast’s partial inhibition of
Tat-induced TNFa production could be particularly useful when
considering this drug as an adjunctive therapy for HAND.
Complete inhibition of TNFa production is undesirable, as this
could negatively impact TNFa’s ability to perform efficient host
defense. In this respect, it has been shown that TNFa blockade can
cause reactivation of tuberculosis (TB) in animal models [95], and
it has also been suggested that inhibition of TNFa in patients with
chronic hepatitis B infection (HBV) could worsen the disease, since
TNFa is involved in viral clearance [95]. Furthermore, inhibition
of TNFa in the context of other neuroinflammatory disorders such
as MS and Alzheimer’s disease (AD) has very recently been shown
to be associated with progressive multifocal leukoencephalopathy
(PML) and demyelination [96]. Taken together, these consider-
ations again emphasize that ibudilast’s partial inhibition of TNFa
could be beneficial, rather than detrimental. In summary, our
findings shed light on the mechanism of ibudilast’s inhibition of
Tat-induced TNFa production in microglial cells and may
Figure 5. Ibudilast inhibits Tat-induced TNFa transcript levels.
BV-2 cells (2.5610
5) were left untreated (NT) or were treated with Tat
(100 nM) for 4 h with or without pre-treatment for 30 min. with
increasing concentrations of ibudilast (Ib) or vehicle (Veh). Total RNA
was collected, reverse transcribed using oligo-dT primers, and
subjected to Real-Time SYBR Green RT-PCR amplification. Fold
induction of TNFa mRNA species was normalized to those of GAPDH
and presented as a function of the expression level in NT samples. Data
represent mean 6 SEM of values derived from three replicates from a
single representative experiment. Statistical significance (***, p,0.001
or *, p,0.05) is denoted as compared to Tat-treated samples.
doi:10.1371/journal.pone.0018633.g005
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management of HAND.
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